<table>
<thead>
<tr>
<th><strong>Title</strong></th>
<th>Live birth rate, multiple pregnancy rate, and obstetric outcomes of elective single and double embryo transfers: Hong Kong experience</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Author(s)</strong></td>
<td>Chai, J; Yeung, TWY; Lee, VCY; Li, RHW; Lau, EYL; Yeung, WSB; Ho, PC; Ng, EHY</td>
</tr>
<tr>
<td><strong>Citation</strong></td>
<td>Hong Kong Medical Journal, 2014, v. 20 n. 2, p. 102-106</td>
</tr>
<tr>
<td><strong>Issued Date</strong></td>
<td>2014</td>
</tr>
<tr>
<td><strong>URL</strong></td>
<td><a href="http://hdl.handle.net/10722/201044">http://hdl.handle.net/10722/201044</a></td>
</tr>
<tr>
<td><strong>Rights</strong></td>
<td>Hong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press.; This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.</td>
</tr>
</tbody>
</table>
A B S T R A C T

Objective: To compare the live birth rate, multiple pregnancy rate, and obstetric outcomes of elective single and double embryo transfers.

Design: Case series with internal comparisons.

Setting: University affiliated hospital, Hong Kong.

Participants: Between October 2009 and December 2011, 206 women underwent their first in-vitro fertilisation cycle. Elective single embryo transfer was offered to women who were aged 35 years or below, and had endometrial thickness of 8 mm or more and at least two embryos of good quality.

Main outcome measures: Live birth rate, multiple birth rate, and obstetric outcomes.

Results: Among the 206 eligible women, 74 underwent an elective single embryo transfer and 132 a double embryo transfer. The live birth rate was comparable in the two groups, being 39.2% in the elective single embryo transfer group and 43.2% in the double embryo transfer group, while the multiple pregnancy rate was significantly lower in the elective single embryo transfer group than the double embryo transfer group (6.9% vs 40.4%; P<0.001). Gestational ages and birth weights were comparable in the two groups. There was no significant difference between the two groups with respect to the rate of preterm delivery and antenatal complications (27.6% vs 43.9%, respectively; P>0.05).

Conclusion: In this selected population, an elective single embryo transfer policy decreases the multiple pregnancy rate without compromising the live birth rate. The non-significant difference in antenatal complications may be related to the small sample size.

New knowledge added by this study
- Elective single embryo transfer decreased the multiple pregnancy rate without compromising the live birth rate in women with a good prognosis undergoing in-vitro fertilisation.

Implications for clinical practice or policy
- Elective single embryo transfer should be offered to women with a good prognosis and the care provider should promote this policy through education.
Fertilisation and Embryology Authority in the UK recommended reducing the number of embryos that should be transferred in a single IVF treatment cycle from three to two.4

In 2001, ESHRE recommended elective single embryo transfer (eSET) for women aged under 34 years at the time of their first attempt, as soon as they had obtained a top-quality embryo.5 In 2008, the British Fertility Society, in conjunction with the Association of Clinical Embryologists, introduced guidelines for eSET in the UK that aimed to reduce IVF multiple pregnancy rates to less than 10%.6 Meta-analyses have shown that in a selected population, compared with double embryo transfer (DET), eSET could reduce multiple pregnancy rates significantly, without compromising cumulative pregnancy rates.7,8

Our centre offered eSET to eligible women in order to reduce the multiple pregnancy rate. The aim of this study was to compare the live birth rate, multiple pregnancy rate, and obstetric outcomes after eSET and DET in mothers having their first IVF/ intra-cytoplasmic sperm injection (ICSI) attempt.

Methods

This was a retrospective study carried out at the Centre of Assisted Reproduction and Embryology, Queen Mary Hospital, The University of Hong Kong, Hong Kong. Clinical details of all treatment cycles were prospectively entered into a computerised database, and checked for correctness and completeness on a regular basis. For this study, data were retrieved for analysis and ethics committee approval was deemed not necessary for retrospective analysis of data.

Patients

In our programme, a maximum of two embryos were replaced, irrespective of the woman’s age. Women were eligible for eSET if they were ≤35 years of age at the time of the embryo transfer, were undergoing their first IVF cycle, had an endometrial thickness of ≥8 mm, and had at least two good-quality embryos available for transfer or freezing. Good-quality embryos were defined by their morphological features and cleavage rate, and included embryos with less than 25% fragmentation and four cells at day 2. Eligible patients were individually counselled about eSET. Women who opted for eSET would have one embryo replaced (eSET group), while those who opted for DET had two embryos transferred (DET group).

Ovarian stimulation and in-vitro fertilisation/intra-cytoplasmic sperm injection procedures

All women were treated either with the long gonadotropin-releasing hormone (GnRH) agonist protocol or the GnRH antagonist protocol for pituitary down-regulation. The details of the long protocol for the ovarian stimulation regimen, handling of gametes, as well as standard insemination and ICSI were as previously described.9 In short, women received buserelin (Suprecur; Hoechst, Frankfurt, Germany) nasal spray 150 μg 4 times a day starting from the mid-luteal phase of the cycle preceding the treatment cycle, followed by human menopausal gonadotropins (hMG) or recombinant follicle-stimulating hormone (FSH) for ovarian stimulation after return of a period. In the GnRH antagonist protocol, after confirming a basal serum oestradiol level, ovarian stimulation was started with either hMG or recombinant FSH. Ganirelix (NV Organon; Swords Co, Dublin, Ireland) 250 μg was started from the sixth day of stimulation. The starting dose of gonadotropin was based on the baseline antral follicle count.

Transvaginal ultrasonography was used to monitor the ovarian response. When the mean diameter of the leading follicle reached 18 mm and there were at least three follicles reaching a mean diameter of 16 mm or more, human chorionic gonadotropin (hCG; Pregnyl; Organon, Oss, The Netherlands) 5000 or 10000 units or Ovidrel (Merck Serono, Modugno, Italy) 250 μg was given and oocytes were collected about 36 hours later. Fertilisation was carried out in vitro either by...
TABLE 1. Demographic and clinical characteristics of the patients referred for sperm cryopreservation (n=130)*

<table>
<thead>
<tr>
<th></th>
<th>eSET (n=74)</th>
<th>DET (n=132)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of women (years)</td>
<td>31.8 ± 2.0</td>
<td>32.7 ± 2.3</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>21.2 ± 2.6</td>
<td>21.9 ± 2.6</td>
<td>0.221</td>
</tr>
<tr>
<td>Primary subfertility (%)</td>
<td>72.9</td>
<td>71.0</td>
<td>0.822</td>
</tr>
<tr>
<td>Duration of infertility (years)</td>
<td>4.2 ± 2.6</td>
<td>3.9 ± 2.2</td>
<td>0.754</td>
</tr>
<tr>
<td>Indication for IVF</td>
<td>0.212</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>eSET (n=74)</th>
<th>DET (n=132)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endometriosis</td>
<td>7 (9.5)</td>
<td>6 (4.5)</td>
<td></td>
</tr>
<tr>
<td>Tuboperitoneal factor</td>
<td>18 (24.3)</td>
<td>25 (18.9)</td>
<td></td>
</tr>
<tr>
<td>Male factor</td>
<td>36 (48.6)</td>
<td>61 (46.2)</td>
<td></td>
</tr>
<tr>
<td>Unexplained</td>
<td>9 (12.2)</td>
<td>20 (15.2)</td>
<td></td>
</tr>
<tr>
<td>Mixed factors</td>
<td>4 (5.4)</td>
<td>20 (15.2)</td>
<td></td>
</tr>
<tr>
<td>Basal FSH (IU/L)</td>
<td>7.6 ± 1.8</td>
<td>8.0 ± 3.1</td>
<td>0.971</td>
</tr>
<tr>
<td>Baseline antral follicle count</td>
<td>14.7 ± 8.1</td>
<td>13.9 ± 8.3</td>
<td>0.449</td>
</tr>
<tr>
<td>Percentage of ICSI (%)</td>
<td>35.1</td>
<td>34.1</td>
<td>0.880</td>
</tr>
</tbody>
</table>

Abbreviations: DET = double embryo transfer; eSET = elective single embryo transfer; FSH = follicle-stimulating hormone; ICSI = intra-cytoplasmic sperm injection; IVF = in-vitro fertilisation
* Data are shown as mean ± standard deviation, %, or No. (%)

TABLE 2. Cycle characteristics*

<table>
<thead>
<tr>
<th></th>
<th>eSET (n=74)</th>
<th>DET (n=132)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of stimulation (days)</td>
<td>10.9 ± 2.5</td>
<td>10.9 ± 2.0</td>
<td>0.657</td>
</tr>
<tr>
<td>Dosage of gonadotropins (IU)</td>
<td>2048 ± 920</td>
<td>2139 ± 779</td>
<td>0.065</td>
</tr>
<tr>
<td>Oestradiol level (pmol/L)</td>
<td>11 986 ± 406</td>
<td>9545 ± 4232</td>
<td>0.065</td>
</tr>
<tr>
<td>No. of oocytes retrieved</td>
<td>10.9 ± 4.3</td>
<td>10.6 ± 5.7</td>
<td>0.245</td>
</tr>
<tr>
<td>No. of embryos at day 2</td>
<td>6.7 ± 3.0</td>
<td>6.1 ± 3.8</td>
<td>0.060</td>
</tr>
<tr>
<td>No. of good-quality embryos</td>
<td>4.1 ± 2.0</td>
<td>3.3 ± 1.7</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Abbreviations: DET = double embryo transfer; eSET = elective single embryo transfer
* Data are shown as mean ± standard deviation

conventional insemination or ICSI depending on semen parameters. Women were allowed to have replacement of at most two embryos 2 days after oocyte retrieval. A progesterone pessary (Endometrin 100 mg twice per day; Ferring Pharmaceuticals, Parsippany [NJ], US) was administered from the day of embryo transfer for 2 weeks to enable luteal support. Pregnancies were confirmed by positive urine hCG tests and transvaginal ultrasonographic evidence of a gestational sac.

Collection of clinical information

Clinical information including age, body mass index, basal serum levels of FSH, and baseline antral follicle counts were collected. During IVF treatment, such data included days of stimulation, total dosage of gonadotropin, oestradiol level on day of hCG, number of oocytes retrieved, number of available embryos, number of good-quality embryos, as well as pregnancy and miscarriage rates.

Clinically, pregnancy was defined as the presence of a gestational sac by ultrasonography, whereas the miscarriage rate per clinical pregnancy was defined as the proportion of patients whose pregnancy failed to develop before 20 weeks of gestation. Pregnancy outcome was collected from all pregnant women by a postal questionnaire or by phone. Live birth was defined as the delivery of a fetus with signs of life after 24 completed weeks of gestational age, and the multiple pregnancy rate was calculated as the number of multiple pregnancies divided by the number of clinical pregnancies, expressed as a percentage. Obstetric outcomes including antenatal complications, gestational age at delivery, mode of delivery, and birth weight were also recorded.

Statistical analysis

The primary outcome measure was the live birth rate and secondary outcomes included the multiple pregnancy rate and obstetric outcomes. Statistical analysis for the comparison of mean values was performed using Mann-Whitney and Student’s t tests, as appropriate. The Chi squared and Fisher’s exact tests were used to compare categorical variables. Statistical analysis was carried out using the Statistical Package for the Social Sciences (Windows version 20.0; SPSS Inc, Chicago [IL], US). A two-tailed P value of <0.05 was considered statistically significant.

Results

In all, 206 women undergoing their first IVF cycle from October 2009 to December 2011 met the inclusion criteria. A total of 74 women chose eSET and 132 chose DET. Patient and cycle characteristics are shown in Tables 1 and 2, respectively. Women who opted for eSET were significantly younger than those opting for DET, and had a significantly higher proportion of good-quality embryos than those in the DET group.

The IVF and obstetric outcomes are shown in Table 3. Among women with eSET, 40 (54.1%) had a positive pregnancy test; two were biochemical pregnancies, eight miscarried, and one was an ectopic pregnancy. There was one pair of monozygotic and one pair of dizygotic twins in the eSET group. In women having DET, the positive pregnancy test rate was 58.3% (n=77/132); there were nine biochemical pregnancies, seven miscarriages, and four ectopic pregnancies. In the DET group, the multiple pregnancy rate was 40.4%, which was significantly higher than that in the eSET group (P<0.001). There were two sets of triplets, of which one underwent fetal reduction to a singleton and the other had fetal reduction to twins. One woman in the eSET group...
and four in the DET group were lost to follow-up for their obstetric outcomes. Overall, the live birth rate was comparable in the eSET and DET groups (39.2% vs 43.2%, respectively).

The mean gestational age at birth and the median birth weight were not significantly different in the eSET group compared with the DET group (38.6 ± 2.2 vs 37.9 ± 2.3 weeks and 2950 [interquartile range, 2830-3157] g vs 2785 [2475-3200] g, respectively). The preterm delivery rate (defined as delivery at <37 weeks) and the frequencies of antenatal complications (including gestational diabetes, gestational hypertension, pre-eclampsia, and placenta praevia) were higher in the DET group, although the difference did not reach statistical significance.

### Discussion

The risk of multiple pregnancy has been a concern in IVF/ICSI as it is associated with adverse maternal and neonatal outcomes. This is the first study reporting live birth rates and obstetric outcomes after eSET and DET in a selected population in Hong Kong. Our study confirms recent literature findings, by showing that eSET can significantly reduce the multiple pregnancy rate without adversely affecting the live birth rate in young women with good ovarian function. No triplets were observed in the eSET group, but rather unexpectedly it did contain two pairs of twins; one was monzygotic and one dizygotic. Dizygotic twin pregnancy following a single embryo transfer was a rare event, and suggestive of a spontaneous pregnancy occurring concurrently with one due to IVF. The multiple pregnancy rate of 40.4% in the DET group and the live birth rates in our study (39.2% and 43.2% in the eSET and DET groups, respectively) were similar to or higher than those previously reported.

Our study showed that the obstetric outcomes were not significantly different in the two groups. Antenatal complications were more common in the DET group (43.9% vs 27.6% in eSET group), although the difference did not reach statistical significance (P=0.142). Regrettably, data on the Apgar score, neonatal intensive care unit admissions, and perinatal mortality were not available. A recent meta-analysis by Grady et al showed that eSET singletons had a higher birth weight and lower preterm birth rate than DET singletons, which was postulated to be related to the vanishing twin. Our study failed to demonstrate the difference but this could be attributed to the small sample size.

Our study was limited by its retrospective nature and small sample size. Also, women having eSET were significantly younger than those having DET, which might lead to possible confounding.

The younger mean age in the eSET group could explain the higher number of good-quality embryos available for transfer, which might have an impact on the cumulative pregnancy rate. The cumulative pregnancy rate was not always included as many women still had frozen embryos, but this would be an important aspect to look into in the future. Another bias was that women were allowed to choose between one or two embryos to transfer, instead of allocation by randomisation. Nonetheless, it reflected the actual situation in our centre. Blastocyst transfer is not routinely performed in our unit, because of the possible increased risk of congenital abnormalities and preterm labour, although the pregnancy and live birth rates of the fresh cycle may be higher than those following early cleavage stage transfer.

The eSET policy is increasingly being applied and in a country like Belgium, the law requires eSET for all patients aged under 36 years during their first two IVF attempts. In Hong Kong, eSET is not imposed and suitable women were given the choice of eSET and DET with detailed counselling. From our data, only a third of the women chose eSET, which suggests that such women are still resistant to eSET. Child et al found that 41% of women having assisted reproductive technology were actually inclined to prefer a twin pregnancy, and some women waiting for IVF treatment viewed severe child disability outcomes more desirable than having no child at all. This barrier might be overcome by providing

*Abbreviations: DET = double embryo transfer; eSET = elective single embryo transfer
* Data are shown as No. (%) or mean ± standard deviation, unless otherwise stated
educational material to women so as to improve their knowledge on outcomes and risks of multiple pregnancies. The feasibility of eSET also relies on improving outcomes with cryopreserved embryos and the technique on vitrification. Information from the present study may also improve the uptake of eSET in the unit.

Our study confirms that when compared with DET, eSET can reduce the rate of multiple pregnancies without compromising the live birth rate in the fresh cycle. Elective SET should be offered to patients with a good prognosis and IVF centres should promote it, whenever appropriate, through provider and patient education.

Acknowledgements

The authors would like to thank Mr TM Cheung for data collection.

Declaration

No conflicts of interest were declared by the authors.

References

4. HFEA reduces maximum number of embryos transferred in single IVF treatment from three to two [press release]. Human Fertilisation and Embryology Authority; 2001 Aug 8.